The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.